

Helix BioMedix Announces Launch of New Corporate Website

February 3, 2009 - Bothell, Washington

BOTHELL, Wash. - (BUSINESS WIRE) - Helix BioMedix (OTCBB:[HXBM -News](#)), a leader in bioactive peptides, today announced the launch of a new corporate Website designed to reflect the Company's expanded vision as a premier biotech company. The Website (www.helixbiomedix.com) includes general information on the Company, as well as provides visitors with a detailed look at both Helix BioMedix's pharmaceutical program and its cosmeceutical SmartPeptide™ ingredients which are included in a growing number of prestige and mass market skin care products.

"Our new website provides both current and potential customers, partners and investors a comprehensive view of our technologies, intellectual property and development programs," commented R. Stephen Beatty, President and Chief Executive Officer of Helix BioMedix. "As we have stated in the past, our goal is to become a premier provider of innovative bioactive peptides for use in both pharmaceutical and cosmeceutical applications, and I believe that our new Website better reflects the key messaging of the Company, our achievements and the future opportunities available to us."

About Helix BioMedix, Inc.

Helix BioMedix, Inc. is a biopharmaceutical company with an extensive library of diverse bioactive peptides and patents covering six distinct classes and hundreds of thousands of peptide sequences. Our mission is to enrich clinical practice and the patient/consumer experience by developing topically-applied products which offer the health, beauty and safety benefits of our advanced bioactive small molecule technology. Our vision is to be recognized as the world leader in the identification, qualification and commercialization of natural and synthetic peptides.

Our core competencies include peptide design, synthesis and characterization together with assay development, screening, tissue culture and microbiology, leveraged through relationships with contract research organizations and peptide manufacturers. We have the capability to take our product development programs from the theoretical concept to a validated and qualified skin care active ingredient fully validated as to efficacy and safety. Applications for Helix BioMedix peptides include anti-aging cosmeceutical skin care and acne treatment as well as other topical anti-infective pharmaceuticals and wound healing applications. In addition, we are developing finished, peptide-based products to market with our partners. Striking and SmartPeptide are trademarks of Helix BioMedix, Inc. P.A.C Perfect is a trademark of DermaVentures, LLC. Tego is a registered trademark of Evonik Goldschmidt GmbH.

More information about the company and its proprietary peptides may be found on the company's website at www.helixbiomedix.com.

Forward-Looking Statements

This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that the company expects, believes or anticipates may occur in the future, including statements related to its potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully raise additional capital, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, continue developing marketable peptide-based products and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in the company's reports and other filings with the Securities and Exchange Commission. Such filings are available on the company's website or at www.sec.gov. Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.

Contacts:

Investor Contact:

Shelton Group Investor Relations
Ryan Bright, 972-239-5119 X 159
rbright@sheltongroup.com

Company Contact:

Helix BioMedix, Inc.
R. Stephen Beatty, 425-402-8400

President and CEO
sbeatty@helixbiomedix.com